Inhaled therapies,
instant relief.

Miist Therapeutics is setting a new standard in acute care with inhaled therapies that work in seconds, not hours

Our Platform

Delivering instant relief through the peripheral lung

The lining of the peripheral lung is only 1 cell thick, enabling immediate absorption of drugs into the bloodstream. This route of administration can be as fast and efficient as an IV injection.

Anatomical diagram of human lungs showing labeled parts including the trachea, central lung region, and peripheral lung regions against a light blue background.

Existing inhalers can't target the lung periphery

Traditional inhalers produce particles that are too large to reach the lung periphery. Instead they get trapped in the central lung, where systemic absorption is minimal and slow.

Miist unlocks peripheral lung administration

Miist's inhaler produces particles that are 50% smaller, allowing them to bypass the central lung and deposit in the peripheral region.

Rapid bloodstream entry relieves symptoms in seconds.

Here, the particles pass immediately into the bloodstream, reaching peak plasma levels within seconds.

Speed

Peak plasma levels reached in less than 30 seconds

Ease

Instant relief in the convenience of a breath

Safety

Produces sterile aqueous particles using vibration, not heat

Pipeline

Building a portfolio of rapid-acting therapies

Leveraging our proprietary platform inhaler, Miist is uniquely positioned to develop the fastest-acting treatments across a broad range of therapeutic indications.

Program

Preclinical

Phase 1

Phase 2

Phase 3

Approved

MST01

Smoking Cessation

Smoking causes:

30%

of all cancer deaths

90%

of lung cancer deaths

80%

of COPD cases

8 million

deaths per year

Stop cravings, solve addictions

Cigarette cravings and withdrawals are the main events that cause relapse. These are acute events with a critical treatment window that only lasts for 15 minutes from their onset. With a time-to-relief of >30 minutes, today’s existing therapies are simply too slow to be effective.

MST01 is clinically validated to eliminate 93% of a patient's cravings within 2 minutes. This represents the most important advancement to the field of smoking cessation in over 2 decades.

In addition to the rapid craving relief, MST01 employs a programmed dosing protocol that automatically reduces the delivered dose by 1.1%, daily, over the course of a 12 week treatment. This allows the patient's neuronal nicotinic receptor (nAChR) count to naturally downregulate back to the baseline of a non-smoker, treating the underlying neurobiological cause of the addiction.

MST02

Migraine

Migraines cause:

cause of disabled living

4.5

episodes per month

2 billion

migraines every year in US

40 million

Americans live with migraine

>90% of today's migraine prescriptions are for pills that take 2-4 hours to be fully absorbed into the body. By this time, the migraine is fully established, hard to treat, and the patient has lost hours of their day.

MST02 is an inhaled migraine therapy in preclinical development. With the potential to deliver peak migraine relief within 5 minutes, MST02 is poised to be a clear best-in-class treatment.